-
1Academic Journal
Authors: V. A. Solodkiy, A. Yu. Pavlov, A. G. Dzidzaria, A. D. Tsibulskii, В. А. Солодкий, А. Ю. Павлов, А. Г. Дзидзария, А. Д. Цыбульский
Source: Cancer Urology; Том 19, № 4 (2023); 86-96 ; Онкоурология; Том 19, № 4 (2023); 86-96 ; 1996-1812 ; 1726-9776
Subject Terms: радикальная простатэктомия, prostate cancer, salvage brachytherapy, high dose brachytherapy, radical prostatectomy, рак предстательной железы, спасительная брахитерапия, высокодозная брахитерапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1717/1495; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1717/1377; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1717/1378; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1717/1379; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1717/1380; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1717/1381; Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17–48. DOI:10.3322/caac.21763; Huang J., On-Ting Chan E., Liu X. et al. Global trends of prostate cancer by age, and their associations with Gross Domestic Product (GDP), Human Development Index (HDI), smoking, and alcohol drinking. Clin Genitourin Cancer 2023;21(4):e261–70. DOI:10.1016/j.clgc.2023.02.003; Roberts M.J., Chatfield M.D., Hruby G. et al. Event-free survival after radical prostatectomy according to PSMA PET and EAU Biochemical Recurrence Risk Groups. BJU Int 2022;130(Suppl 3): 32–9. DOI:10.1111/bju.15762; Петровский Н.В., Глыбочко П.В., Аляев Ю.Г. и др. Локальный рецидив рака предстательной железы после радикальной простатэктомии. Урология 2017;(4):85–90. DOI:10.18565/urol.2017.4.85-90; Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–7. DOI:10.1001/jama.281.17.1591; Moreira D.M., Presti J.C., Aronson W.J. et al. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol 2009;182(5):2250–5. DOI:10.1016/j.juro.2009.07.022; Preisser F., Chun F.K.H., Pompe R.S. et al. Persistent prostatespecific antigen after radical prostatectomy and its impact on oncologic outcomes. Eur Urol 2019;76(1):106–14. DOI:10.1016/j.eururo.2019.01.048; Sugino F., Nakane K., Kawase M. et al. Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients. J Robot Surg 2023;17(5):2441–9. DOI:10.1007/s11701-023-01670-3; Le Guevelou J., Magne N., Counago F. et al. Stereotactic body radiation therapy after radical prostatectomy: current status and future directions. World J Urol 2023;41(11):3333–44. DOI:10.1007/s00345-023-04605-7; Falagario U.G., Abbadi A., Remmers S. et al. Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy. JAMA Netw Open 2023;6(9):e2332900. DOI:10.1001/jamanetworkopen.2023.32900; Furrer M.A., Sathianathen N., Gahl B. et al. Oncological outcomes after attempted nerve-sparing radical prostatectomy (NSRP) in patients with high-risk prostate cancer are comparable to standard non-NSRP: a longitudinal long-term propensity-matched singlecentre study. BJU Int 2024;133(1):53–62. DOI:10.1111/bju.16126; Ploussard G., Fossati N., Wiegel T. et al. Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature. Eur Urol Oncol 2021;4(2): 150–69. DOI:10.1016/j.euo.2021.01.001; Buchser D., Gomez-Iturriaga A., Melcon I. et al. Salvage highdose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy. J Contemp Brachytherapy 2016;8(6):477–83. DOI:10.5114/jcb.2016.64441; Petersen P.M., Cook A.D., Sydes M.R. et al. Salvage radiation therapy after radical prostatectomy: analysis of toxicity by dosefractionation in the RADICALS-RT trial. Int J Radiat Oncol Biol Phys 2023;117(3):624–9. DOI:10.1016/j.ijrobp.2023.04.032; Benziane-Ouaritini N., Zilli T., Giraud A. et al. Prostatectomy bed image-guided dose-escalated salvage radiotherapy (SPIDER): an international multicenter retrospective study. Eur Urol Oncol 2023;6(4):390–8. DOI:10.1016/j.euo.2023.02.013; Thompson I.M., Valicenti R.K., Albertsen P. et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 2013;190(2):441–9. DOI:10.1016/j.juro.2013.05.032; Morton G., McGuffin M., Chung H.T. et al. Prostate high doserate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 2020;146:90–6. DOI:10.1016/j.radonc.2020.02.009; Johansson B., Olsén J.S., Karlsson L. et al. High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center. J Contemp Brachytherapy 2021;13(3):245–53. DOI:10.5114/jcb.2021.105846; NCCN guidelines insights. Prostate cancer, version 1.2023. Available at: https://education.nccn.org.; EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6.; Клинические рекомендации. Рак предстательной железы, 2021–2022–2023 (20.01.2023). Доступно по: http://disuria.ru.; Strouthos I., Karagiannis E., Zamboglou N., Ferentinos K. Highdose-rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome. Cancer Rep (Hoboken) 2021;5(1):e1450. DOI:10.1002/cnr2.1450; Sargos P., Chabaud S., Latorzeff I. et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 2020;21(10):1341–52. DOI:10.1016/S1470-2045(20)30454-X; Staal F.H.E., Janssen J., Brouwer C.L. et al. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol. BMC Cancer 2022;22(1):416. DOI:10.1186/s12885-022-09493-5; Soror T., Melchert C., Rades D. et al. Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiation. J Contemp Brachytherapy 2023;15(3):159–65. DOI:10.5114/jcb.2023.128845; https://oncourology.abvpress.ru/oncur/article/view/1717
-
2Academic Journal
Authors: A. D. Kaprin, S. A. Ivanov, O. B. Karyakin, A. A. Obuhov, V. A. Biryukov, N. B. Borysheva, D. B. Sanin, O. G. Lepilina, A. L. Smolkin, A. V. Dem’yanovich, N. G. Minaeva, N. V. Mikhaylovskiy, А. Д. Каприн, С. А. Иванов, О. Б. Карякин, А. А. Обухов, В. А. Бирюков, Н. Б. Борышева, Д. Б. Санин, О. Г. Лепилина, А. Л. Смолкин, А. В. Демьянович, Н. Г. Минаева, Н. В. Михайловский
Source: Cancer Urology; Том 16, № 4 (2020); 112-119 ; Онкоурология; Том 16, № 4 (2020); 112-119 ; 1996-1812 ; 1726-9776
Subject Terms: внутритканевая лучевая терапия, recurrent prostate cancer, prostate-specific antigen, salvage brachytherapy, high-dose-rate brachytherapy, interstitial radiotherapy, рецидив рака предстательной железы, простатический специфический антиген, сальважная брахитерапия, спасительная брахитерапия, высокомощностная брахитерапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1316/1221; Guidlines of Europen Assosiation of Urology, 2020, www.uroweb.org.; Состояние онкологической помощи населению России в 2018 году. Под редакцией А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Москва; 2019.; NCCN Prostate cancer Brachytherapy. NCCN Guidelines for patients Prostate cancer, 2019.; Брахитерапия. Под общей редакцией акад. РАН А. Д. Каприна, чл.-корр. РАН Ю.С. Мардынского. МРНЦ им. А. Ф. Цыба - филиал ФГБУ "НМИЦ радиологии»" Минздрава России. Обнинск, 2017. ISBN 978-5-901968-28-4; Tisseverasinghe SA, Crook JM. The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer. Transl Androl Urol 2018;7(3):414-435. DOI:10.21037/tau.2018.05.09.; Солодкий В.А., Павлов А.Ю., Цыбульский А.Д. Спасительная брахитерапия высокой мощности дозы при местном рецидиве рака предстательной железы после радикальных радиотерапевтических методов лечения. Онкоурология, Т. 12, № 4 (2016), с. 81-6,. DOI:10.17650/1726-9776-2016-12-4-81-86.; Терапевтическая радиология: национальное руководство / под ред. А. Д. Каприна, Ю. С. Мардынского. - М.: ГЭОТАР-Медиа, 2018. - 704 с. - ISBN 978-5-9704-4658-4.; Olarte A., Cambeiro M., Moreno-Jiménez M. et al. Dose escalation with external beamradiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy 2016;15(2):127–35. DOI:10.1016/j.brachy.2015.12.008. PMID: 26832677.; Matei DV, Ferro M, Jereczek-Fossa BA, et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int 2015;94(4):373–82. DOI:10.1159/000371893.PMID: 25765848.; Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1): 2– 10. PMID: 9886580.; Каприн А.Д., Галкин В.Н., Иванов С.А. Роль брахитерапии в лечении локализованных форм рака предстательной железы. Biomedical Photonics, 2015. Т.4, №4. С. 21-26.; https://oncourology.abvpress.ru/oncur/article/view/1316
-
3Academic Journal
Authors: V. A. Solodkiy, A. Yu. Pavlov, A. D. Tsybulskiy, A. G. Dzidzariya, A. S. Pchelintsev, В. А. Солодкий, А. Ю. Павлов, А. Д. Цыбульский, А. Г. Дзидзария, А. С. Пчелинцев
Source: Cancer Urology; Том 15, № 2 (2019); 73-76 ; Онкоурология; Том 15, № 2 (2019); 73-76 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-2
Subject Terms: высокая мощность дозы, brachytherapy, salvage brachytherapy, high dose rate, брахитерапия, спасительная брахитерапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/903/851; Liu J., Kaidu M., Sasamoto R. et al. Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy forprostate cancer: single institution experience and outcomes. J Radiat Res 2016;57(3):280–7. DOI:10.1093/jrr/rrw003.; Gabriele D., Jereczek-Fossa B.A., Krengli M. et al. Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier. Radiat Oncol 2016;11(1):23. DOI:10.1186/s13014-0160599-5.; Olarte A., Cambeiro M., Moreno-Jiménez M. et al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy 2016;15(2):127–35. DOI:10.1016/j.brachy.2015.12.008.; Garibaldi E., Gabriele D., Maggio A. et al. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. Panminerva Med 2016;58(2):121–9.; Bolla M., Van Tienhoven G., Warde P. et al. External irradiation with or without longterm androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010;11(11):1066–73. DOI:10.1016/S1470-2045(10)70223-0.; Jo Y., Fujii T., Hara R. et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int 2012;109(6):835–9. DOI:10.1111/j.1464-410X.2011.10519.x.; Matei D.V., Ferro M., Jereczek-Fossa B.A. et al. Radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int 2015;94(4):373– 82. DOI:10.1159/000371893.; Berlin A., Fernandez M.I. Avances en el tratamiento de cancer de prostata resistente a la castracion: enfasis en nuevas terapias hormonales. Rev Méd Chile 2015;2:143–9.; Grado G.L., Collins J.M., Kriegshauser J.S. et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2–10.; Aaronson D.S., Yamasaki I., Gottschalk A. et al. Salvage permanent perineal radioactiveseed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009;104(5):600–4. DOI:10.1111/j.1464-410X.2009.08445.x.; Lee B., Shinohara K., Weinberg V. et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California, San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67(4):1106–12. DOI:10.1016/j.ijrobp.2006.10.012.; Morton J., Loblaw G., D’Alimonte A. et al. Focal Salvage high dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure: results from a prospective clinical trial. Int J Rad Oncol Biol Phys 2018;102 (3):33–40.; Kollmeier M.A., McBride S., Taggar A. et al. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: a comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy 2017;16(6): 1091–8. DOI:10.1016/j.brachy.2017.07.013.; https://oncourology.abvpress.ru/oncur/article/view/903
-
4Academic Journal
Authors: V. A. Solodkiy, A. Yu. Pavlov, A. D. Tsybul’skiy, В. А. Солодкий, А. Ю. Павлов, А. Д. Цыбульский
Source: Cancer Urology; Том 12, № 4 (2016); 81-86 ; Онкоурология; Том 12, № 4 (2016); 81-86 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4
Subject Terms: простатический специфический антиген, prostate cancer recurrence, salvage brachytherapy, life-saving brachytherapy, high dose brachytherapy, high dose rate brachytherapy, interstitial radiation therapy, prostate-specific antigen, рецидив рака предстательной железы, сальважная брахитерапия, спасительная брахитерапия, высокодозная брахитерапия, высокомощностная брахитерапия, внутритканевая лучевая терапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/599/608; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/599/321; Liu J., Kaidu M., Sasamoto R. et al. Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy forprostate cancer: single institution experience and outcomes. J Radiat Res 2016;57(3):280–7. DOI:10.1093/jrr/rrw003. PMID: 26983988.; Gabriele D., Jereczek-Fossa B.A., Krengli M. et al. Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier. Radiat Oncol 2016;11(1):23. DOI:10.1186/s13014-016-0599-5. PMID: 26911291.; Olarte A., Cambeiro M., Moreno-Jiménez M. et al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes. Brachytherapy 2016;15(2):127–35. DOI:10.1016/j.brachy.2015.12.008. PMID: 26832677.; Garibaldi E., Gabriele D., Maggio A. et al. External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. Panminerva Med 2016;58(2):121–9. PMID: 26785374.; Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol 2010;11:1066–73.; Jo Y., Fujii T., Hara R. et al. Salvage highdose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int 2012;109(6):835–9. DOI:10.1111/j.1464-410X.2011.10519.x. PMID: 21933327.; Matei D.V., Ferro M., Jereczek-Fossa B.A. et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int 2015;94(4):373–82. DOI:10.1159/000371893. PMID: 25765848.; Berlin A., Fernandez M.I. Avances en el tratamiento de cancer de prostata resistente a la castracion: enfasis en nuevas terapias hormonales. Rev Méd Chile 2015;(2):143–9.; Grado G.L., Collins J.M., Kriegshauser J.S. et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53(1):2–10. PMID: 9886580.; Aaronson D.S., Yamasaki I., Gottschalk A. et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009;104(5):600–4. DOI:10.1111/j.1464-410X.2009.08445.x. PMID: 19245439.; Lee B., Shinohara K., Weinberg V. et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California, San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67(4):1106–12. DOI:10.1016/j.ijrobp.2006.10.012. PMID: 17197119.; Nguyen P.L., Chen R.C., Clark J.A. et al. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: a prospective Phase II study. Brachytherapy 2009;8(4):345–52. DOI:10.1016/j.brachy.2009.01.004. PMID: 19428311.; Beyer D.C. Brachytherapy for recurrent prostate cancer after radiation therapy. Semin Radiat Oncol 2003;13(2):158–65. DOI:10.1053/srao.2003.50015. PMID: 12728445.; https://oncourology.abvpress.ru/oncur/article/view/599